Cite

    Amin, A. et al. (2022). Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis. Current medical research and opinion. pp. 2131-2140. [Online].